Welcome to our dedicated page for Arbutus Biopharma Corporation news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma Corporation stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (cHBV). Utilizing its extensive expertise in virology, Arbutus focuses on developing a portfolio of drug candidates with multiple mechanisms of action aimed at curing Hepatitis B virus (HBV) disease. The company's lead RNA interference (RNAi) therapeutic, imdusiran (AB-729), targets HBV proteins to reduce viral antigens and reawaken the host's immune response. Imdusiran is currently undergoing multiple Phase 2a clinical trials, demonstrating promising results in reducing hepatitis B surface antigen (HBsAg) levels and achieving functional cures in a subset of patients.
Arbutus leverages its proprietary lipid nanoparticle (LNP) technology and expertise in RNAi therapeutics to develop innovative treatments. Beyond HBV, the company has a robust pipeline that includes AB-101, an oral PD-L1 inhibitor, currently in Phase 1a/1b trials. This compound aims to enable controlled checkpoint blockade while minimizing systemic safety issues.
Recent clinical data highlight the potential of Arbutus' combination therapies. In the IM-PROVE I trial, imdusiran combined with pegylated interferon alfa-2a (IFN) and nucleos(t)ide analogue (NA) therapy demonstrated sustained HBsAg loss in some patients, suggesting a path toward a functional cure. Another study, IM-PROVE II, showed that combining imdusiran with VTP-300, an immunotherapeutic, resulted in meaningful reductions in HBsAg levels and the discontinuation of NA therapy in a significant number of patients.
Financially, Arbutus maintains a strong position with a cash runway extending into the first quarter of 2026. They are actively involved in ongoing patent litigation to protect their LNP technology, seeking fair compensation for its use in mRNA COVID-19 vaccines by Moderna and Pfizer/BioNTech.
Arbutus continues to engage in strategic collaborations and partnerships to advance its mission of curing HBV and other chronic infectious diseases. For more detailed information, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will release its Q3 2020 financial results and corporate update on November 5, 2020. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast through Arbutus' website, and a recorded version will be available afterward. The company focuses on developing a cure for chronic hepatitis B and treatments for coronaviruses, including COVID-19. For further details, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced participation in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on October 20, 2020, at 10:00 am ET. The presenters include William Collier (CEO), Dr. Michael Sofia (CSO), Dr. Gaston Picchio (CDO), David Hastings (CFO), and Michael McElhaugh (CBO). The live webcast can be accessed on Arbutus' website, with an archived replay available post-conference. Arbutus is focused on developing a cure for chronic hepatitis B virus (HBV) infection and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma (Nasdaq: ABUS) will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include President and CEO William Collier, Chief Scientific Officer Dr. Michael Sofia, Chief Development Officer Dr. Gaston Picchio, and Chief Financial Officer David Hastings. The event will be accessible via webcast on the company’s investor website, with a replay available after the conference. Arbutus focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include William Collier (President and CEO), Dr. Michael Sofia (Chief Scientific Officer), Dr. Gaston Picchio (Chief Development Officer), and David Hastings (Chief Financial Officer). The chat will be accessible via a live webcast on Arbutus' website, with an archived replay available post-conference. The company focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reports favorable results from ongoing Phase 1a/1b clinical trials for its RNAi drug AB-729 targeting chronic hepatitis B virus (HBV) infection. A single 90 mg dose showed a mean HBsAg reduction of 1.23 log10 IU/mL at week 12, indicating both efficacy and safety. The company continues to evaluate multiple dosing regimens, with results from 60 mg cohorts forthcoming. Over 250 million people are affected by HBV globally, showcasing a critical need for effective treatments.
Arbutus Biopharma Corporation (Nasdaq: ABUS), focused on curing chronic hepatitis B virus (HBV) infection and developing therapies for coronaviruses, will participate in a virtual fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 10:30 am ET.
Key presenters include William Collier (CEO), Dr. Michael Sofia (CSO), Dr. Gaston Picchio (CDO), and David Hastings (CFO). The live webcast will be accessible on Arbutus' website and will feature a replay after the event.
Assembly Biosciences and Arbutus Biopharma have partnered to conduct a clinical trial evaluating the combination of Assembly's ABI-H0731 and Arbutus' AB-729 for treating chronic hepatitis B virus (HBV) infection. This Phase 2 trial aims to assess safety, pharmacokinetics, and antiviral activity among 60 patients over 48 weeks. The collaboration is expected to enhance therapeutic options for HBV and address the significant unmet medical need in this area, given HBV's global prevalence affecting over 250 million people.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has reported progress in its clinical trials and has provided a corporate update. The Phase 1a/1b trial for AB-729, an RNAi agent targeting chronic hepatitis B, is on track, with results from new cohorts expected in the latter half of 2020. The company also anticipates completing IND-enabling studies for AB-836, an oral HBV capsid inhibitor, by year-end. Financially, they hold $84 million in cash, with guidance extended through mid-2022. Net loss for Q2 2020 was $17.1 million, a decrease from $26.1 million in Q2 2019.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has scheduled its Q2 2020 financial results and conference call for August 7, 2020. The press release will be issued at 7:30 a.m. ET, followed by the conference call/webcast at 8:45 a.m. ET. Live access to the call can be found on Arbutus' website, with an archived version available afterward. Arbutus focuses on developing a cure for chronic hepatitis B virus infections and treatments for coronaviruses, including COVID-19. For more details, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced positive results from its Phase 1a/1b clinical trial of AB-729, aimed at treating chronic hepatitis B virus (HBV) infection. The study showed a mean 0.99 log10 IU/mL reduction in HBsAg at week 12 with normal liver enzyme levels. The company is now advancing to multi-dose cohorts, dosing 60 mg of AB-729, and plans to release further data in late 2020. Interim findings suggest AB-729 is both effective and well-tolerated, supporting the goal of a combined therapy for chronic HBV.
FAQ
What is the current stock price of Arbutus Biopharma Corporation (ABUS)?
What is the market cap of Arbutus Biopharma Corporation (ABUS)?
What is Arbutus Biopharma's primary focus?
What is imdusiran (AB-729)?
What are the key recent achievements of Arbutus Biopharma?
What is the status of Arbutus' financial condition?
What technologies does Arbutus leverage for its treatments?
What are the current projects Arbutus Biopharma is working on?
Has Arbutus formed any strategic partnerships?
What is the significance of Arbutus' patent litigation?
How successful have Arbutus' clinical trials been?
Where can more information about Arbutus Biopharma be found?
